Trimetazidine in Pulmonary Artery Hypertension

Status Recruiting

Clinical Trial Summary

Pulmonary artery hypertension (PAH) is a chronic and progressive disease that affects 15 persons per million. Although current therapy has improve disease prognosis, PAH still has a poor survival, with a median survival of 2.8 years after diagnosis. In the last few years new key elements in PAH pathogenesis have been discovered, such as the role of metabolism in disease onset and progression. In fact, PAH pulmonary smooth muscle cells switch into a glycolytic phenotype which resembles the metabolism of cancer cells. The investigators hypothesis is that "fatty acid oxidation inhibition reverts the PAH adverse phenotype by restoring mitochondrial function and morphology, decreasing proliferation and restoring apoptosis susceptibility in pulmonary smooth muscle cells "

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02102672
Study type	Interventional
Source	Pontificia Universidad Catolica de Chile
Contact	Pablo F Castro, MD
Phone	+56223543334
Email	pcastro@med.puc.cl
Status	Recruiting
Phase	Phase 2
Start date	March 2014
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05056532` - Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
Active, not recruiting	`NCT06003244` - High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)	N/A
Active, not recruiting	`NCT06072417` - HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)	N/A
Recruiting	`NCT02966665` - : Vascular Function in Health and Disease	Phase 1
Recruiting	`NCT00502398` - Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?	N/A
Completed	`NCT04456998` - GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)	Phase 2
Not yet recruiting	`NCT06035861` - Endothelial Cell Activation and Total Pulmonary Resistance in PAH	N/A
Not yet recruiting	`NCT03138863` - Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)	N/A
Withdrawn	`NCT06122922` - Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)	Phase 2
Recruiting	`NCT03195543` - Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
Completed	`NCT04337671` - Impact of Aerobic Training on Sleep Quality and Aerobic Fitness in Male Patients With Pulmonary Artery Hypertension	N/A
Completed	`NCT03198910` - Retrospective Data Analysis of Data From the Zurich PH Registry
Completed	`NCT03979482` - Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH
Active, not recruiting	`NCT05996302` - HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)	N/A
Active, not recruiting	`NCT06084559` - HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)	N/A
Withdrawn	`NCT02684786` - A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension	Phase 1
Not yet recruiting	`NCT06258850` - REstoration of VItamin D in Pulmonary Arterial Hypertension	Phase 4
Completed	`NCT04094272` - Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
Active, not recruiting	`NCT01763112` - Training With Whole Body Vibration Device in Patients With PAH	N/A
Completed	`NCT01581086` - Vascular Subphenotypes of Lung Disease in HIV & COPD	N/A